Plain-English translation of NCT05444452 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a newer heart stent called GENOSS—which has a thinner metal structure and a special coating that dissolves over time—works as well as or better than a standard stent (Xience) that's already widely used. The GENOSS stent is designed to reduce long-term complications by allowing the polymer coating to completely absorb within 9 months, leaving only the metal frame behind.
Even with modern drug-coated stents, some patients experience blood clots or other problems months or years after the procedure. Researchers believe that using a thinner stent with a coating that breaks down completely over time might reduce these late complications and improve long-term safety.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the new GENOSS stent or the standard Xience stent during your coronary procedure—both are placed the same way. You'll then be followed up with visits and imaging (likely angiography) to check how well the stent is working and to monitor for any complications over the first 9 months and beyond.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
South Korea
Sponsor
Samsung Medical Center
Collaborators
Genoss Company Limited, Suwon, Korea
Enrollment target
~850 participants
Started
April 2022
Primary completion
June 2027
Age range
19 Years and older
Last updated on clinicaltrials.gov in July 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hyeon-Cheol Gwon, MD, PhD
Samsung Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.